Current Problems in Cancer
Volume 30, Issue 6 , Pages 244-254 , November 2006

Does QOL Provide the Same Information as Toxicity Data?

  • Mashele Huschka
    • ,
  • Kelli Burger

      Affiliations

    • Corresponding Author InformationAddress correspondence to Dr. Jeff A. Sloan, Mayo Clinic, Section of Biostatistics, Department of Health Science Research, 200 First St. S.W., Rochester, MN 55905, USA

References 

  1. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys. 2000;47:1–12
  2. National Cancer Institute. June 1, 1999. Common Toxicity Criteria Manual. Available from: http://ctep.cancer.gov/forms/CTCManual-v4-10-4-99.pdf. Accessed February 27, 2006.
  3. National Cancer Institute. December 12, 2003. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/forms/ CTCAEv3.pdf. Accessed February 27, 2006.
  4. Cox DR, Fitzpatrick R. Quality-of-life assessment: can we keep it simple?. J R Stat Soc. 1992;155:353–393
  5. Beardsley T. A war not won. Sci Am. 1994;270:130–138
  6. Tannock I. Treating the patient, not just the cancer. N Engl J Med. 1987;3:1534–1535
  7. American Society for Clinical Oncology Health Services Research Committee. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol. 1996;14:671–679
  8. Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R. Quality of life assessment in clinical trials: guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience (MRC Cancer Trials Office). Eur J Cancer. 1997;33:20–28
  9. Symonds T, Berzon R, Marquis P, Rummans TA Clinical Significance Consensus Meeting Group. The clinical significance of quality of life results: practical considerations for specific audiences. Mayo Clin Proc. 2002;77:572–583
  10. Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 1996;5:496–502
  11. Blanch MM, Atherton PJ, Novotny PJ, Maurer MJ, Parkinson J, Jett J, et al. Less is more III: quality of life measures and toxicity data in a series of North Central Cancer Treatment Group (NCCTG) lung cancer clinical trials. Am Soc Clin Oncol. 2003;22:528;abstract 2124.
  12. Cella D, Bullinger M, Scott C, Barofsky I Clinical Significance Consensus Meeting Group. Group vs. individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clin Proc. 2002;77:384–392
  13. Varricchio CG, Sloan JA. The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. J Natl Cancer Inst. 2002;94:1184–1185
  14. Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol. 2003;22:2461–2468
  15. Morton RF, Sloan JA, Grothey A, Sargent DJ, McLeod H, Green EM, et al. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. 2005 ASCO Annual Meeting, abstract 8087.
  16. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. February 2006. Available from: http://www.fda.gov/cder/guidance/5460dft.pdf. Accessed February 27, 2006.
  17. Kaba H, Fukuda H, Yamamoto S, Ohashi Y. Reliability at the National Cancer Institute: Common Toxicity Criteria version 2.0. Gan To Kagaku Ryoho. 2004;31:1187–1192
  18. Sneeuw KC, Aaronson NK, Sprangers MA, Detmar SB, Wever LD, Schornagel JH. Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses. Br J Cancer. 1999;81:87–94
  19. Frost MH, Sloan JA. Quality of life measurements: a soft outcome: or is it?. Am J Manag Care. 2002;8:S574–S579
  20. Marquie L, Raufaste E, Lauque D, Marine C, Ecoiffier M, Sorum P. Pain rating by patients and physicians: evidence of systematic pain miscalibration. Pain. 2003;102:289–296
  21. Macquart-Moulin G, Viens P, Bouscary ML, Genre D, Resbeut M, Gravis G, et al. Discordance between physicians’ estimations and breast cancer patients’ self-assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer. 1997;76:1640–1645
  22. Huschka MM, Mandrekar SJ, Schaefer PL, et al. A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group (NCCTG) lung cancer clinical trials. Cancer 2006 (accepted).
  23. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1978;1:373–378
  24. Hollen P, Gralla R, Kris M, Potanovich L. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale. Eur J Cancer. 1993;29:S51–S58
  25. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Sympt Manag. 1995;10:1–8
  26. Morrow GR. A patient report measure for the quantification of chemotherapy induced nausea and emesis: psychometric properties of the Morrow Assessment of Nausea and Emesis (MANE). Br J Cancer. 1992;19:S72–S74
  27. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–579
  28. Rhodes VA, McDaniel RW. The index of nausea, vomiting and retching: a new format of the index of nausea and vomiting. Oncol Nurs Forum. 1999;26:889–894
  29. Osoba D. A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results. Med Care. 2002;40:31–38
  30. Luoma ML, Hakamies-Blomqvist L, Sjostrom J, Mouridsen H, Pluzanska A, Malmstrom P, et al. Physical performance, toxicity, and quality of life as assessed by the patient. Acta Oncol. 2002;41:44–49
  31. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  32. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chron Dis. 1981;34:585–597
  33. Sloan JA, Loprinzi CL, Laurine JA, Novotny PJ, Vargas-Chanes D, Krook JE, et al. A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index. J Clin Oncol. 2001;19:3539–3546
  34. Auchter RM, Scholtens D, Adak S, Wagner H, Cella DF, Mehta MP. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Int J Radiat Oncol Biol Phys. 2001;50:1199–1206
  35. Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995;12:199–220
  36. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from eastern cooperative oncology group study 5592. J Clin Oncol. 2003;21:1536–1543
  37. Frost MH, Huschka M. Quality of life from a patient’s perspective: can we believe the patient?. Curr Probl Cancer. 2005;29:326–330
  38. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138

PII: S0147-0272(06)00054-7

doi: 10.1016/j.currproblcancer.2006.08.003

Current Problems in Cancer
Volume 30, Issue 6 , Pages 244-254 , November 2006

Article Tools

* Image Usage & Resolution